The Balanced Body LifestyleThe Balanced Body Lifestyle™

INDIVIDUAL PEPTIDE PROFILE

Cagrilintide

A long-acting synthetic analog of amylin, a hormone co-secreted with insulin that helps regulate appetite and gastric emptying. Cagrilintide is engineered for once-weekly dosing and is under active investigation by Novo Nordisk, alone and combined with semaglutide in a product called CagriSema.

Compound type: Peptide analogAmylin Receptor Agonist ResearchResearch Reality Check: Phase 3 Trials, Investigational
Back to Individual Peptide Profiles

WHAT IT IS

Cagrilintide is a long-acting amylin analog built using fatty-acid acylation technology similar to that used in semaglutide, extending its action to support once-weekly injection.

It amplifies signaling through amylin-related pathways that promote satiety and slow gastric emptying, working through a mechanism distinct from, but complementary to, GLP-1 receptor agonism.

Novo Nordisk has studied cagrilintide both as a standalone investigational drug and combined with semaglutide, marketed in trials as CagriSema, for obesity and type 2 diabetes. FDA status: Cagrilintide, alone or as CagriSema, is not currently FDA-approved.

WHAT RESEARCHERS ARE STUDYING IT FOR

Published and reported human trials have evaluated:

  • Body weight reduction in adults with overweight or obesity, including in combination with semaglutide
  • Glycemic control and weight reduction in adults with type 2 diabetes
  • Cagrilintide-semaglutide as an add-on to basal insulin therapy
  • Comparative weight-loss outcomes against other approved incretin-based medications

PROPOSED BIOLOGICAL MECHANISMS

Amylin signaling in the brainstem contributes to feelings of fullness and reduces food intake independent of the GLP-1 pathway, which is why combining an amylin analog with a GLP-1 receptor agonist is of pharmacological interest.

Slowed gastric emptying is a proposed contributor to the appetite-reducing effect, alongside central nervous system signaling.

In combination trials, cagrilintide and semaglutide are thought to act on complementary appetite-regulating circuits, which researchers propose may explain the larger weight reductions reported when the two are combined compared with either alone.

AREAS OF RESEARCH INTEREST

  • Whether CagriSema's weight-loss advantage over single-agent therapies is confirmed and durable across broader populations
  • Long-term cardiovascular and safety outcomes with extended use
  • Gastrointestinal tolerability, a known class effect of amylin and GLP-1 based therapies
  • Regulatory review timelines and eventual approval status in different countries

WHAT THE EVIDENCE CURRENTLY SUGGESTS

A phase 3 randomized, placebo-controlled trial published in the New England Journal of Medicine reported that cagrilintide-semaglutide produced substantially greater weight reduction than placebo in adults with overweight or obesity and type 2 diabetes, alongside improved glycemic control.

Additional phase 3 trials have examined cagrilintide-semaglutide as an add-on to basal insulin and in broader obesity populations, generally reporting weight-loss results larger than those seen with semaglutide alone in earlier trials, though cross-trial comparisons should be read cautiously.

Gastrointestinal side effects, including nausea and vomiting, have been reported in these trials, consistent with the broader incretin drug class. Cagrilintide and CagriSema remain investigational and have not completed the regulatory approval process.

Randomized trial data, still pre-approval

STRONG TRIAL RESULTS DO NOT EQUAL AN APPROVED MEDICATION YET

Cagrilintide has more published, randomized, placebo-controlled human trial evidence than most compounds in this library, which puts it in a different evidence category than early-stage research peptides.

That evidence supports meaningful weight reduction and improved glycemic measures in the populations studied so far.

It does not yet mean cagrilintide or CagriSema has cleared regulatory review, and an approved label with defined dosing and safety monitoring does not exist yet.

Research Reality Check

Evidence Strength: Multiple Published Human Trials, Not Yet FDA-Approved

What we know

Randomized, placebo-controlled phase 3 trials of cagrilintide-semaglutide have reported substantially greater body weight reduction and improved glycemic measures compared with placebo in adults with overweight, obesity or type 2 diabetes, with gastrointestinal side effects consistent with the broader incretin drug class.

What remains uncertain

Long-term cardiovascular outcomes, durability of weight loss after stopping treatment, and the eventual regulatory approval status and label details for cagrilintide and CagriSema in various countries.

Educational commentary, not personal testimonial

The Balanced Body Lifestyle Take

Cagrilintide and the CagriSema combination represent some of the most rigorously studied compounds in this library, and the trial data is genuinely compelling. We think it is worth following closely as it moves through regulatory review rather than treating it as already settled.

If cagrilintide has caught your attention, reach out to us. We can talk through what drew you to it, walk through your questions, and look at what the published trials do and do not show.

QUESTIONS PEOPLE OFTEN ASK

SOURCES & FURTHER READING

Peptide Education Consultation

Interested in learning more about peptides? Schedule an educational consultation with Vince Angelo to discuss the information and ask questions.

Schedule an Educational Consultation

EDUCATIONAL NOTICE

The Balanced Body Lifestyle™ provides peptide and wellness information for educational purposes only. Content is intended to help readers better understand emerging research, established evidence and areas of scientific uncertainty. It is not medical advice, diagnosis, treatment guidance or a recommendation to use any medication, peptide or research compound. Decisions involving prescription medications or investigational compounds should be discussed with a qualified healthcare professional.

THE BALANCED BODY LIFESTYLE

A healthy life is built on balance.

Back to Individual Peptide ProfilesPeptide Education Library